Coherus Oncology, Inc. (CHRS) Shareholders’ equity 2016–2025
Coherus Oncology, Inc. (CHRS) shareholders’ equity at each fiscal year-end, per SEC filings.
$61.0MFY2025 · since FY2016: $20.5M → $61.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $61.0M | +146.2% |
| FY2024 | -$132.0M | +31.8% |
| FY2023 | -$193.4M | -40.8% |
| FY2022 | -$137.4M | -240.6% |
| FY2021 | $97.7M | -65.2% |
| FY2020 | $281.0M | +167.1% |
| FY2019 | $105.2M | +372.6% |
| FY2018 | -$38.6M | -226.4% |
| FY2017 | $30.5M | +48.8% |
| FY2016 | $20.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice